Every 8-K that The Chemours Company (CC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CC filings page.
Chemours Co (CC) entered into a Settlement Agreement with the State of North Carolina and 11 local entities to resolve claims relating to PFAS and other emissions from its Fayetteville Works facility, as well as certain PFAS contamination elsewhere in the state, including from aqueous film-forming foam. The agreement calls for aggregate payments of $455 million over 15 years, beginning within 30 days of execution, and remains subject to court orders dismissing the covered claims. Under existing cost-sharing arrangements, Chemours will bear 50% of the settlement payments, with DuPont and Corteva sharing the remaining 50%. Chemours states its approximately $180 million net present value share is covered by existing accruals, and expects about $50 million of payments in the next twelve months. The Settlement Amount will count as about $210 million of qualified spend under the parties’ $4 billion MOU cap, and combined with a 2025 New Jersey settlement eliminates the need for further contributions to the MOU escrow account, including Chemours’ $50 million contribution previously due in September 2026.
Chemours Co (CC) furnished an investor presentation outlining its strategy, segment performance and capital structure as of the second quarter of 2026. For Q2 2026, the company generated $1.59 billion in net sales and $247 million in Adjusted EBITDA, but recorded a net loss attributable to Chemours of $274 million. Adjusted EPS was $0.42, while free cash flow reached $114 million, a 128% year‑over‑year increase, with 46% free cash flow conversion.
The presentation details the “Pathway to Thrive” plan targeting more than $250 million of cost reductions from 2024–2027, 5%+ sales CAGR and long‑term net leverage below 3.0x. Trailing twelve‑month net sales were $5.80 billion with Adjusted EBITDA of $733 million, including Titanium Technologies net sales of $2.39 billion and Adjusted EBITDA of $725 million at a 34% margin.
Chemours highlights growth in low‑GWP Opteon refrigerants, data center and semiconductor applications, and a mid‑cycle Adjusted EBITDA floor target of $400 million for Titanium Technologies. The company reports gross debt of $3.9 billion, net debt of $3.2 billion, and Q2 2026 net leverage of 4.4x, supported by €230 million of recent term‑loan repayment and approximately $287 million initial net proceeds from the Kuan Yin site sale, while continuing to resolve legacy environmental and PFAS‑related matters through settlements and mitigation commitments.
The Chemours Company reported Q2 2026 results with net sales of $1.59 billion, down 1% year over year, and a net loss of $274 million ($1.81 per share), narrower than a $380 million loss a year earlier. Adjusted net income was $64 million and Adjusted EBITDA $247 million, both below prior‑year levels.
Free cash flows rose to $114 million from $50 million, lifting the free cash flow conversion rate to 46% and contributing to a net leverage ratio of 4.4x on a trailing twelve‑month Adjusted EBITDA basis. Consolidated gross debt was $3.9 billion and total liquidity was $1.6 billion, including $671 million of unrestricted cash and $953 million of revolver capacity.
Thermal & Specialized Solutions delivered $591 million of sales and a 36% Adjusted EBITDA margin, aided by pricing despite softer Opteon™ aftermarket demand. Titanium Technologies saw modest sales and EBITDA gains from TiO2 price increases, while Advanced Performance Materials experienced lower sales and a 48% EBITDA decline, offset by strong growth in Performance Solutions serving data center and semiconductor markets.
Results reflected significant litigation and environmental charges related to PFAS matters and settlements, partly offset by a gain on Kuan Yin land sales. For full‑year 2026, Chemours projects 1–5% net sales growth, $775–$825 million Adjusted EBITDA, free cash flow conversion above 25%, and a net leverage ratio of around 3.8x by year‑end.
The Chemours Company entered into a proposed settlement with the U.S. Environmental Protection Agency and the West Virginia Department of Environmental Protection to resolve claims relating to PFAS emissions and other alleged activities at several facilities. Chemours agreed to pay a $22.5 million civil penalty in three annual installments, beginning within 30 days after court approval of a Consent Decree, and to fund $90 million of additional mitigation projects over 15 years to reduce PFAS emissions and support alternative drinking water solutions.
The company will expand off-site drinking water programs in West Virginia, Ohio and New Jersey, which it expects will increase existing environmental reserves. Chemours also resolved litigation brought by the West Virginia Rivers Coalition for less than $1 million. The settlement, which does not constitute an admission of liability or fault by Chemours, remains subject to public notice, comment and final court approval.
The Chemours Company reported first quarter 2026 results showing modest sales growth but a larger loss. Net sales were $1.381 billion, up 1% year over year, while net loss attributable to Chemours widened to $29 million, or $(0.19) per diluted share. Adjusted EBITDA was $169 million, a 2% increase.
Thermal & Specialized Solutions led performance with record first-quarter net sales of $568 million, up 22%, and Adjusted EBITDA of $190 million, up 35%, driven by strong Opteon and Freon refrigerant demand. Titanium Technologies net sales fell 6% to $559 million and Adjusted EBITDA dropped to $18 million, while Advanced Performance Materials net sales declined 17% to $243 million with Adjusted EBITDA of $5 million.
Chemours ended March 31, 2026 with $4.2 billion in gross debt and $563 million in unrestricted cash, for net debt of $3.62 billion and a net leverage ratio of about 4.9x trailing Adjusted EBITDA. After quarter-end it received about $287 million from selling most of its Kuan Yin site, using part of the cash to repay €140 million of term loans. The company guides second-quarter Adjusted EBITDA to $220–$250 million and reaffirms full-year 2026 Adjusted EBITDA of $800–$900 million and net sales growth of 3–5% over 2025.
The Chemours Company reported results of its April 24, 2026 annual meeting. Shareholders approved the new 2026 Equity and Incentive Plan, which reserves up to 6,375,275 shares for a range of stock-based awards to employees, contractors, and non-employee directors.
All eleven director nominees were elected for one-year terms. Shareholders also approved the advisory say-on-pay vote on executive compensation, approved the equity plan, and ratified PricewaterhouseCoopers LLP as independent registered public accounting firm.
The Chemours Company completed a private Offering of $700,000,000 aggregate principal amount of 7.875% senior unsecured notes due 2034. The notes were sold to qualified institutional buyers and are senior unsecured obligations guaranteed by a subsidiary.
Chemours used the net proceeds, together with cash on hand, to redeem $188,000,000 of 5.750% senior notes due 2028 for an aggregate redemption price of about $189,800,000 plus interest. The remaining net proceeds are expected to fund the redemption of 5.375% senior notes due 2027 for an aggregate redemption price of about $500,300,000, plus accrued interest.
The Chemours Company filed a Form 8-K to report a private debt financing. The company launched and priced an upsized offering of $700,000,000 aggregate principal amount of 7.875% senior unsecured notes due 2034, increased from a previously announced $600,000,000 offering size.
The notes mature on March 15, 2034 and will pay interest semi-annually on March 15 and September 15, starting September 15, 2026. Chemours intends to use the net proceeds to redeem its outstanding 5.375% senior notes due 2027 and partially redeem its outstanding 5.750% senior notes due 2028. The notes are being sold in a private offering to qualified institutional buyers under Rule 144A and to certain non-U.S. investors under Regulation S.
The Chemours Company reported fourth quarter 2025 net sales of $1.3 billion, down 2% year over year, and a net loss of $47 million, or $0.31 per diluted share. Adjusted EBITDA was $128 million versus $168 million a year earlier.
For full year 2025, net sales were $5.8 billion, essentially flat, but results swung to a net loss of $386 million, or $2.57 per share, from net income of $69 million, largely due to litigation-related and environmental charges. Adjusted EBITDA slipped modestly to $742 million from $768 million. TSS delivered record net sales of $2.1 billion and Adjusted EBITDA of $670 million, while TT and APM saw sharp profit declines. Net debt was $3.5 billion with a 4.7x net leverage ratio. For 2026, Chemours guides to 3–5% net sales growth, Adjusted EBITDA of $800–$900 million, and Free Cash Flow Conversion above 25%.
The Chemours Company agreed to sell ten parcels of land in Kuan Yin, Taiwan, for a total purchase price of approximately $360 million. The sale is being executed through four real estate sale and purchase agreements between a Chemours subsidiary and four affiliated buyers, and the company plans to use the cash proceeds to reduce its debt obligations.
The transaction is expected to close in one or more stages by mid-year 2026, subject to closing conditions and local regulatory approvals, including environmental conditions. The agreements include customary representations, warranties, covenants, indemnities, and termination provisions for industrial property deals, and were negotiated on an arm’s-length basis with no other material relationships between Chemours and the buyers. Chemours also issued a press release outlining the property sale.
The Chemours Company furnished an update on its business by providing a press release and prepared remarks covering Q3 2025 financial results. The materials are included as Exhibits 99.1 and 99.2 and are designated as “furnished,” not “filed,” under the Exchange Act.
The company plans to post an investor presentation and the prepared remarks to its investor relations website by 8:00 a.m. Eastern Daylight Time on Friday, November 7, 2025, aligned with its scheduled conference call.
The Chemours Company adopted an Executive Severance Policy effective October 28, 2025. The policy covers executive officers and designated employees who are involuntarily terminated without Cause or resign for Good Reason. Eligible participants receive accrued and unpaid base salary, bonus or incentive compensation, and vacation pay. The CEO is eligible for a cash severance equal to 2.0 times the sum of base salary, target annual incentive opportunity, and annualized health care subsidy; other executive officers and employees receive 1.0 times that sum. A prorated annual cash incentive is payable based on actual performance for the portion of the year worked.
The policy requires a signed release of claims to receive benefits. It does not supersede any change in control agreements and does not alter the treatment of outstanding equity awards, which remain governed by existing plans and award agreements.
The Chemours Company amended its credit agreement, extending the maturity of its $1,050,000,000 senior secured U.S. dollar term loan (Term Loan B-3) from August 18, 2028 to October 15, 2032. The loan’s pricing was reset to either adjusted Term SOFR + 3.50% or adjusted base rate + 2.50%, at the company’s election.
Separately, several wholly owned European subsidiaries entered a receivables purchase agreement with BNP Paribas Factor allowing sales of eligible receivables up to an aggregate outstanding balance of €180,000,000. The initial term runs through October 14, 2026 with automatic one-year extensions, and Chemours acceded to joint and several liability for seller obligations. Receivables are sold at their nominal amount less customary deductions, with applicable interest and fees payable to BNP.
The Chemours Company reported changes to its board leadership. The Board of Directors has appointed Independent Director Mary Cranston as Chair of the Board and Alister Cowan as Lead Independent Director, both effective September 2, 2025. These moves follow the departure of former Chair Dawn Farrell, who has accepted a role with the Canadian government as Chief Executive Officer of the newly created Major Projects Office under the Building Canada Act. The filing confirms this is a governance update and does not discuss changes to the company’s business strategy or financial results.
The Chemours Company reported that Dawn Farrell, Chair of its Board of Directors, has decided to resign from the Board effective September 2, 2025. She is leaving to accept an appointment with the Canadian government as Chief Executive Officer of the newly created Major Projects Office launched by the Prime Minister of Canada under the Building Canada Act.
The Board received her notice on August 29, 2025, and has not yet chosen a successor as Chair. The company states that an announcement about who will become the next Board Chair will be made in the future.
Settlement overview. On 3 Aug 2025 Chemours, DuPont and Corteva entered a proposed Judicial Consent Order with New Jersey that would resolve all state PFAS and legacy-site contamination claims. The Companies will pay an aggregate $875 million in cash to the state, spread over 25 years starting no earlier than 1 Jan 2026; the total present value, discounted at 8%, is about $500 million. Chemours will fund 50%, DuPont 35.5% and Corteva 14.5%.
Funding & security. Site-specific Remediation Funding Sources will be backed by surety bonds, and DuPont/Corteva will establish a separate Reserve Fund (71%/29%) for future remediation. A parallel Insurance Proceeds MOU lets DuPont and Corteva purchase Chemours’ rights to $150 million of potential PFAS insurance recoveries; after repayment plus a fee, further proceeds are split 50/50. Chemours expects existing escrowed cash and the assigned insurance proceeds to cover its settlement payments through at least 2030.
Next steps & impact. The deal needs public notice, comment and court approval and contains no admission of liability. It reduces legal uncertainty and staggers cash outflows, but long-term PFAS exposure, possible additional remediation costs and regulatory shifts remain key risks, as outlined in the forward-looking-statement section.